{"filing":{"accession_number":"0001193125-26-288752","cik":"0001956827","ticker":"AAVXF","company_name":"Abivax S.A.","form":"6-K","filing_date":"2026-06-29","report_date":null,"primary_document":"d110874d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1956827/000119312526288752/d110874d6k.htm"},"events":[{"id":14750,"run_id":13140,"accession_number":"0001193125-26-288752","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"This is a press release announcing topline results from ABTECT Maintenance Part 2, a Phase 3 clinical trial of obefazimod for ulcerative colitis. The disclosure reports efficacy and safety data from a material clinical milestone—specifically, positive results in a refractory patient population and expanded safety database—that would affect a reasonable investor's assessment of the company's lead drug candidate and regulatory pathway. The company explicitly states it remains \"on track to submit its NDA to the U.S. Food and Drug Administration in the fourth quarter of 2026,\" making these trial results directly relevant to near-term value drivers. While this is not a financial earnings release in the traditional sense, it is a material clinical results announcement that functions as a discrete event disclosure of significant business importance.","company_name":"Abivax S.A.","ticker":"AAVXF","filing_date":"2026-06-29","form":"6-K","submitted_at":null,"items":[{"id":12276,"accession_number":"0001193125-26-288752","item_number":"EX-99.1","item_title":"d110874dex991.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release announcing topline results from ABTECT Maintenance Part 2, a Phase 3 clinical trial of obefazimod for ulcerative colitis. The disclosure reports efficacy and safety data from a material clinical milestone—specifically, positive results in a refractory patient population and expanded safety database—that would affect a reasonable investor's assessment of the company's lead drug candidate and regulatory pathway. The company explicitly states it remains \"on track to submit its NDA to the U.S. Food and Drug Administration in the fourth quarter of 2026,\" making these trial results directly relevant to near-term value drivers. While this is not a financial earnings release in the traditional sense, it is a material clinical results announcement that functions as a discrete event disclosure of significant business importance.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-29T21:23:38.391248+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12276,"accession_number":"0001193125-26-288752","item_number":"EX-99.1","item_title":"d110874dex991.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release announcing topline results from ABTECT Maintenance Part 2, a Phase 3 clinical trial of obefazimod for ulcerative colitis. The disclosure reports efficacy and safety data from a material clinical milestone—specifically, positive results in a refractory patient population and expanded safety database—that would affect a reasonable investor's assessment of the company's lead drug candidate and regulatory pathway. The company explicitly states it remains \"on track to submit its NDA to the U.S. Food and Drug Administration in the fourth quarter of 2026,\" making these trial results directly relevant to near-term value drivers. While this is not a financial earnings release in the traditional sense, it is a material clinical results announcement that functions as a discrete event disclosure of significant business importance.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-29T21:23:38.391248+00:00","company_name":"Abivax S.A.","ticker":"AAVXF","filing_date":"2026-06-29"}]}